Myeloma Center

phase 1 multidose study of dacetuzumab (SGN-40; humanized anti-CD40 mAb) in patients with multiple myeloma.

Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N.

Haematologica. 2010 Feb 4. [Epub ahead of print]PMID: 20133895 [PubMed - as supplied by publisher]Related articlesFree article

Conflicts of interest, authorship, and disclosures in industry-related scientific publications.

Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA.

Mayo Clin Proc. 2010 Feb;85(2):197-9; author reply 201-4. No abstract available.PMID: 20118399 [PubMed - indexed for MEDLINE]Related articles

Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.

Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, Jayabalan D, Niesvizky R, Jagannath S, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ.

Cancer Immun. 2010 Jan 29;10:4.PMID: 20108890 [PubMed - in process]Related articlesFree article

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.

Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L.

J Clin Oncol. 2010 Jan 1;28(1):132-5. Epub 2009 Nov 9.PMID: 19901114 [PubMed - indexed for MEDLINE]Related articles

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.

Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S.

Clin Cancer Res. 2009 Aug 15;15(16):5250-7. Epub 2009 Aug 11.PMID: 19671864 [PubMed - indexed for MEDLINE]Related articles

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

Leukemia. 2009 Nov;23(11):2147-52. Epub 2009 Jul 23.PMID: 19626046 [PubMed - indexed for MEDLINE]Related articles

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.

Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV; International Myeloma Working Group.

Blood. 2009 Aug 27;114(9):1729-35. Epub 2009 Jun 26.PMID: 19561323 [PubMed - indexed for MEDLINE]Related articles

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG; IMWG.

Leukemia. 2009 Oct;23(10):1904-12. Epub 2009 Jun 25.PMID: 19554029 [PubMed - indexed for MEDLINE]Related articles

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.

Chen C, Reece DE, Siegel D, Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Richardson P, Matous J, Kumar S, Bahlis NJ, Alsina M, Vescio R, Coutre SE, Pietronigro D, Knight RD, Zeldis JB, Rajkumar V.

Br J Haematol. 2009 Jul;146(2):164-70. Epub 2009 May 26.PMID: 19545290 [PubMed - indexed for MEDLINE]Related articlesFree article

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.

Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S; IMWG.

Leukemia. 2009 Oct;23(10):1716-30. Epub 2009 Jun 4. Review.PMID: 19494840 [PubMed - indexed for MEDLINE]Related articles

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.

Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG; IMWG.

Leukemia. 2009 Sep;23(9):1545-56. Epub 2009 May 7. Review.PMID: 19421229 [PubMed - indexed for MEDLINE]Related articles

Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma.

Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken M, Jagannath S.

Leuk Lymphoma. 2009 Apr;50(4):559-65.PMID: 19373653 [PubMed - indexed for MEDLINE]Related articles

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, Facon T, Olesnyckyj M, Yu Z, Zeldis JB, Knight RD, Dimopoulos MA.

Eur J Haematol. 2009 Jun;82(6):426-32. Epub 2009 Mar 19.PMID: 19302559 [PubMed - indexed for MEDLINE]Related articlesFree article

CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells.

Baughn LB, Di Liberto M, Niesvizky R, Cho HJ, Jayabalan D, Lane J, Liu F, Chen-Kiang S.

J Immunol. 2009 Feb 15;182(4):1810-7.PMID: 19201832 [PubMed - indexed for MEDLINE]Related articlesFree article

Outcome of deferred initial therapy in mantle-cell lymphoma.

Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP.

J Clin Oncol. 2009 Mar 10;27(8):1209-13. Epub 2009 Feb 2.PMID: 19188674 [PubMed - indexed for MEDLINE]Related articles

Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.

Mark T, Martin P, Leonard JP, Niesvizky R.

Expert Opin Investig Drugs. 2009 Jan;18(1):99-104. Review.PMID: 19053886 [PubMed - indexed for MEDLINE]Related articles

Novel agents in myeloma: an exciting saga.

Mark T, Niesvizky R, Coleman M.

Cancer. 2009 Jan 15;115(2):236-42. No abstract available.PMID: 19025986 [PubMed - indexed for MEDLINE]Related articlesFree article

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group.

Leukemia. 2009 Feb;23(2):215-24. Epub 2008 Nov 20. Review.PMID: 19020545 [PubMed - indexed for MEDLINE]Related articles

Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.

Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S, Ely S, Mazumdar M, Cesarman E, Leonard JP, Furman RR, Chen-Kiang S, Niesvizky R.

Br J Haematol. 2008 Dec;143(5):654-60. Epub 2008 Oct 16.PMID: 18950461 [PubMed - indexed for MEDLINE]Related articles

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.

Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC.

Br J Haematol. 2008 Nov;143(4):537-40. Epub 2008 Sep 6.PMID: 18783399 [PubMed - indexed for MEDLINE]Related articles

Aspirin as thromboprophylaxis in myeloma.

Niesvizky R, Martínez-Baños DM.

Leuk Lymphoma. 2008 Aug;49(8):1646-7. No abstract available.PMID: 18766978 [PubMed - indexed for MEDLINE]Related articles

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.

Niesvizky R, Richardson PG, Rajkumar SV, Coleman M, Rosiñol L, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Boral AL, Esseltine DL, Anderson KC, Bladé J.

Br J Haematol. 2008 Sep;143(1):46-53. Epub 2008 Jul 31.PMID: 18673366 [PubMed - indexed for MEDLINE]Related articles

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.

Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, Pearse RN, Harpel J, Shore T, Schuster MW, Leonard JP, Christos PJ, Coleman M, Niesvizky R.

Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8.PMID: 18541199 [PubMed - indexed for MEDLINE]Related articles

The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.

Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E, Giralt S, Jagannath S, Kyle RA, LeGrand S, Pflugmacher R, Raje N, Rajkumar SV, Randall RL, Roodman D, Siegel D, Vescio R, Zonder J, Durie BG; International Myeloma Working Group.

Leukemia. 2008 Aug;22(8):1479-84. Epub 2008 May 29. No abstract available. Erratum in: Leukemia. 2008 Aug;22(8):1649. Randall, L [corrected to Randall, RL].PMID: 18509352 [PubMed - indexed for MEDLINE]Related articles

Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11.

He KL, Deora AB, Xiong H, Ling Q, Weksler BB, Niesvizky R, Hajjar KA.

J Biol Chem. 2008 Jul 11;283(28):19192-200. Epub 2008 Apr 23.PMID: 18434302 [PubMed - indexed for MEDLINE]Related articlesFree article

FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma.

Rutherford SC, Andemariam B, Philips SM, Elstrom RL, Chadburn A, Furman RR, Niesvizky R, Martin P, Fahey TJ, Coleman M, Goldsmith SJ, Leonard JP.

Leuk Lymphoma. 2008 Apr;49(4):719-26.PMID: 18398739 [PubMed - indexed for MEDLINE]Related articles

Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin’s lymphoma.

Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, Coleman M, Leonard JP.

Semin Hematol. 2008 Apr;45(2):126-32. Review.PMID: 18381108 [PubMed - indexed for MEDLINE]Related articles

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.

Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP.

Ann Oncol. 2008 Jul;19(7):1327-30. Epub 2008 Mar 17.PMID: 18349031 [PubMed - indexed for MEDLINE]Related articlesFree article

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.

Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Kaufman TP, Leonard JP.

Cancer. 2008 May 15;112(10):2228-32.PMID: 18338745 [PubMed - indexed for MEDLINE]Related articlesFree article

Re: When you look matters: the effect of assessment schedule on progression-free survival.

Richardson PG, Niesvizky R, Anderson KC, Bladé J.

J Natl Cancer Inst. 2008 Mar 5;100(5):373. Epub 2008 Feb 26. No abstract available.PMID: 18314478 [PubMed - indexed for MEDLINE]Related articlesFree article

Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma.

Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Leonard J, Kaufmann T.

Leuk Lymphoma. 2008 Mar;49(3):447-50.PMID: 18297520 [PubMed - indexed for MEDLINE]Related articles

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group.

Leukemia. 2008 Feb;22(2):414-23. Epub 2007 Dec 20. Review.PMID: 18094721 [PubMed - indexed for MEDLINE]Related articles

Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.

Niesvizky R, Martínez-Baños D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Zafar F, Pekle K, Leonard J, Jayabalan D, Coleman M.

Leuk Lymphoma. 2007 Dec;48(12):2330-7.PMID: 18067007 [PubMed - indexed for MEDLINE]Related articles

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.

Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NC.

Clin Adv Hematol Oncol. 2007 Oct;5(10 Suppl 15):7-19, quiz 21-2. No abstract available.PMID: 18000495 [PubMed - indexed for MEDLINE]Related articles

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.

Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S.

Leukemia. 2008 Jun;22(6):1280-1; author reply 1281-2. Epub 2007 Nov 22. No abstract available.PMID: 18033320 [PubMed - indexed for MEDLINE]Related articles

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators.

N Engl J Med. 2007 Nov 22;357(21):2133-42.PMID: 18032763 [PubMed - indexed for MEDLINE]Related articlesFree article

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M.

Blood. 2008 Feb 1;111(3):1101-9. Epub 2007 Nov 7.PMID: 17989313 [PubMed - indexed for MEDLINE]Related articlesFree article

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.

Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN, Ely S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M.

Br J Haematol. 2007 Sep;138(5):640-3.PMID: 17686058 [PubMed - indexed for MEDLINE]Related articles

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S.

Cancer Res. 2006 Aug 1;66(15):7661-7.PMID: 16885367 [PubMed - indexed for MEDLINE]Related articlesFree article

Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.

Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D, Niesvizky R, Shore T, Schuster MW, Stewart P, Vallabhajosula S, Goldsmith SJ, Leonard JP.

Cancer. 2006 Feb 1;106(3):616-22.PMID: 16362977 [PubMed - indexed for MEDLINE]Related articlesFree article

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.

Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, Knowles DM, Lane J, Chen-Kiang S.

Cancer Res. 2005 Dec 15;65(24):11345-53.PMID: 16357141 [PubMed - indexed for MEDLINE]Related articlesFree article

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K.

Cancer. 2005 Nov 15;104(10):2141-8.PMID: 16206291 [PubMed - indexed for MEDLINE]Related articlesFree article

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.

Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S, Goldsmith SJ.

J Clin Oncol. 2005 Aug 20;23(24):5696-704.PMID: 16110029 [PubMed - indexed for MEDLINE]Related articles

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma.

Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM.

J Clin Oncol. 2005 Aug 1;23(22):5044-51. Epub 2005 Jun 13.PMID: 15955901 [PubMed - indexed for MEDLINE]Related articles

Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.

Vincent L, Jin DK, Karajannis MA, Shido K, Hooper AT, Rashbaum WK, Pytowski B, Wu Y, Hicklin DJ, Zhu Z, Bohlen P, Niesvizky R, Rafii S.

Cancer Res. 2005 Apr 15;65(8):3185-92.PMID: 15833849 [PubMed - indexed for MEDLINE]Related articlesFree article

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation.

Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, Chen YT, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ.

Blood. 2005 Jul 1;106(1):167-74. Epub 2005 Mar 10.PMID: 15761016 [PubMed - indexed for MEDLINE]Related articlesFree article

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC.

Br J Haematol. 2004 Oct;127(2):165-72.PMID: 15461622 [PubMed - indexed for MEDLINE]Related articles

Kyphoplasty enhances function and structural alignment in multiple myeloma.

Lane JM, Hong R, Koob J, Kiechle T, Niesvizky R, Pearse R, Siegel D, Poynton AR.

Clin Orthop Relat Res. 2004 Sep;(426):49-53.PMID: 15346051 [PubMed - indexed for MEDLINE]Related articles

Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage disease.

Niesvizky R.

Semin Oncol. 2003 Apr;30(2 Suppl 5):20-4. Review.PMID: 12776256 [PubMed - indexed for MEDLINE]Related articles

Treatment of Waldenstrom’s macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone.

Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R.

Semin Oncol. 2003 Apr;30(2):270-4.PMID: 12720151 [PubMed - indexed for MEDLINE]Related articles